Urodynamic condition of lower urinary tract in patients with a benign prostatic hyperplasia who use dutasteride

Cover Page

Cite item

Full Text

Abstract

The aim of this research was to study the urodynamic condition of the lower urinary tract in patients with benign prostatic hyperplasia during their use of dutasteride and at a remote time after its completion. The condition of urodynamic of the lower urinary tract was studied in 311 patients. The duration of dutasteride use ranged from 6 to 48 months. The obtained data made it possible to conclude that in the treatment of patients with benign prostatic hypertension with dutasteride it is advisable to prescribe this drug continuously for at least 48 months.

About the authors

Murat M. Iziev

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University”

Author for correspondence.
Email: ad330@mail.ru

postgraduate

Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089

Adel S. Al-Shukri

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University”

Email: ad330@mail.ru

doctor of medical science, professor 

Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089

Vladimir N. Tkachuk

FSBEI HE “Academician I.P. Pavlov First St Petersburg State Medical University”

Email: tkachuk1@yandex.ru

doctor of medical science, professor, honoured science worker of Russian Federation

Russian Federation, 6/9, Lva Tolstogo street, St. Petersburg, 197089

References

  1. Аполихин О.И., Сивков А.В., Бешлиев Д.А., и др. Современные возможности медикаментозного лечения аденомы предстательной железы // Урология. – 2010. – № 2. – C. 54–59. [Apolikhin OI, Sivkov AV, Beshliev DA, et al. Current opportunities of pharmacotherapy ofprostatic adenoma. Urologiia, 2010;(2):54-59. (In Russ.)]
  2. Roehrborn C, Bartsch G, Kirby R, et al. Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative international overview. Urology. 2001;(58):642-650. doi: 10.1016/S0090-4295(01)01402-9.
  3. Han L. Association of physicion speciality and medical therapy for BPH. Med Care. 2014;52(2):128-136. doi: 10.1097/MLR.0000000000000078.
  4. Cindolo L. Efficacy safety of dutasteride for the treatment of BPH. World of Urology. 2015;33(3):441-452. doi: 10.1007/s00345-014-1300-y.
  5. Ткачук В.Н. Медикаментозное лечение доброкачественной гиперплазии предстательной железы. – М.: Медицина для всех, 2009. – 128 с. [Tkachuk VN. Medicamentoznoe lechenie dobrokachestvennoi giperplazii predstatelnoi zhelezy. Moscow: Medicina dla vsekh; 2009. 128 p. (In Russ.)]
  6. Debruyne F, Barkin J, Van Erps P, et al. ARIA-3001, ARIA-3002 study investigators. Efficacy and safety of long term treatment with the dual 5α-inhibitor dutasteride men with BPH. Eur Urology. 2004;4:488-494. doi: 10.1016/j.eururo.2004.05.008.
  7. Ткачук В.Н., Изиев М.М. Оценка эффективности и безопасности длительной терапии дутастеридом больных с доброкачественной гиперплазией предстательной железы // Нефрология. – 2016. – Т. 20. – № 1. – С. 63–68. [Tkachuk VN, Iziev MM. Evaluation the efficacyand safety of long term therapy with dutasteride in patients with benign prostatic hyperplasia. Nephrology. 2016;20(1):63-68. (In Russ.)]
  8. Ткачук В.Н., Ткачук И.Н., Изиев М.М. Состояние внутриорганного кровотока в предстательной железе у больных ДГПЖ на фоне лечения дутастеридом // Урологические ведомости. – 2017. – Т. 7. – Спецвыпуск. – С. 112–113. [Tkachuk VN, Tkachuk IN, Iziev MM. Sostojanie vnutriorgannogo krovotoka v predstatel’noj zheleze u bol’nyh DGPZ na fone lechenija dutasteridom. Urologicheskie vedomosti. 2017;7(suppl.):112-113 (In Russ.)]
  9. Ткачук В.Н., Изиев М.М. Место дутастерида в лечении больных доброкачественной гиперплазией предстательной железы // Урологические ведомости. – 2015. – Т. 5. – № 1. – С. 49. [Tkachuk VN, Iziev MM. Mesto dutasterida v lechenii bol’nyh dobrokachestvennoj giperplaziej predstatel’noj zhelezy. Urologicheskie vedomosti. 2015;5(1):49. (In Russ.)] doi: 10.17816/uroved5149-49.
  10. Ткачук В.Н., Боровец С.Ю., Ткачук И.Н., Изиев М.М. Рациональное лечение доброкачественной гиперплазии предстательной железы: эффективность длительной терапии дутастеридом // Consilium medicum. – 2016. – Т. 18. – № 7. – С. 19–21. [Tkachuk VN, Borovets SYu, Tkachuk IN, Iziev MM. Rational treatment of benign prostatic hyperplasia: efficacy of long term treatment with dutasteride. Consilium Medicum. 2016;18(7):19-21. (In Russ.)]

Copyright (c) 2017 Iziev M.M., Al-Shukri A.S., Tkachuk V.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies